Zixuan Gao, Wenzhan Hao, Jinming Liu, Kejian Li, Yixiang Sun, Xudong Wu, Zirui Luo, Rui Liu, Haoyu Zhang, Nian Liu, Dongmei Zhao and Maosheng Cheng
RSC Med. Chem., 2025,16, 6068-6080
Abstract
We've found a novel class of amide imidazole CYP51 inhibitors with aromatic fused ring hydrophobic side chains and evaluated the antifungal mechanism of the preferred compound B3.
Petr Šlechta, Roman Viták, Pavel Bárta, Kateřina Koucká, Monika Berková, Diana Žďárová, Andrea Petríková, Jiří Kuneš, Vladimír Kubíček, Martin Doležal, Radek Kučera and Marta Kučerová-Chlupáčová
RSC Med. Chem., 2024,15, 4018-4038
From themed collection:
Editor’s Choice Collection
Abstract
A screen of 33 boronic acids identified molecules with antiproliferative activity against androgen-dependent prostate cancer cell line LAPC4. Structural similarity with NSAA raises a question whether nitro group could be substituted for boronic acid.
Chaoman Huang, Zefeng Jin, Bei Zhang, Yuanyuan Zhou, Huiting Lin, Honglan Kang, Guodong Shen and Xin Lv
Org. Biomol. Chem., 2023,21, 4245-4256
Abstract
One-pot synthesis of 4-(imidazol-1-yl)indole derivatives through sequential dearomatization and Ag-catalyzed cyclization/Cs2CO3-mediated addition/aromatization reaction.
Hans J. Oh, John D. Sears, Bose Muthu Ramalingam, Rahman Shah Zaib Saleem, Zachary W. Davis-Gilbert, Mohammed Anwar Hossain, Stella R. Moorman, Durbadal Ohja, Sabian A. Martinez, Jane E. Burdick, Rafael M. Couñago, Nathaniel J. Moorman, Mark T. Heise, Matthew H. Todd and Timothy M. Willson
RSC Med. Chem., 2026, Advance Article
Abstract
Spirodioxolanes were identified as a new series of direct-acting nsP2 helicase inhibitors with activity against alphaviruses. Analogs such as 6b maintained activity against viral mutants with resistance to first-generation nsP2 helicase inhibitors.
Anjie S. Bispat, Fernanda C. Cardoso, Md. Mahadhi Hasan, Yashad Dongol, Ricki Wilcox, Richard J. Lewis, Peter J. Duggan and Kellie L. Tuck
RSC Med. Chem., 2024,15, 916-936
Abstract
A detailed SAR study led to two potent CaV2.2 inhibitors, the sulfonamide derivatives 42 and 45, which showed high plasma stability, low toxicity, favourable CNS MPO scores (4.0–4.4), and strong potency.